Related Experiment Video
Updated: Jan 11, 2026

A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy
Hydroxyurea for Children with Sickle Cell Disease: A Practical Guide for Pediatric Clinicians
Francis Coyne1, John J Strouse2
1Division of Transition Care Medicine, Department of Medicine, University of Rochester, 905 Culver Road, Rochester, NY 14609, USA; Division of Transition Care Medicine, Department of Pediatrics, University of Rochester, Rochester, NY, USA.
None:
Hydroxyurea is the cornerstone therapy for children with sickle cell disease (SCD). Children with sickle cell anemia (SCA; ∼64% of children with SCD) should be started on hydroxyurea as infants and continue treatment throughout childhood. Hydroxyurea reduces acute complications and chronic organ injury in children with SCA. Hydroxyurea may reduce acute complications in children with HbSC and HbSß+ with frequent complications, but the evidence is limited. We recommend a close partnership between the primary care pediatric clinicians and a sickle cell specialist to reduce barriers to starting and maintaining adherence to hydroxyurea.
More Related Videos
05:23Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
Published on: March 14, 2017
08:23Characterization of Sickling During Controlled Automated Deoxygenation with Oxygen Gradient Ektacytometry
Published on: November 5, 2019
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Drug Excretion
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Drug Dosing: Infants and Children
Pharmacokinetics in Pediatric Patients: Drug Distribution
Hemodialysis III: Nursing Management